Evaxion Biotech Company Insiders
| EVAX Stock | USD 3.67 -0.11 -2.91% |
Evaxion Biotech employs about 46 people. The company is managed by 16 executives with a total tenure of roughly 108 years, averaging almost 6.0 years of service per executive, having 2.88 employees per reported executive. Management-performance analysis for Evaxion Biotech AS gives investors another way to evaluate how leadership is influencing execution, capital allocation, and operating discipline. That matters because management quality often influences how well a company responds when business conditions become less favorable.
Evaxion Biotech's Workforce Through the Years
Historical employee data for Evaxion Biotech can give investors another way to assess whether the business is scaling, restructuring, or stabilizing across different operating conditions. Based on the current model, Evaxion is expected to maintain about 50 employees by April 2026.Macro event markers
Management Team Effectiveness
The company has return on total asset (ROA) of -28.23 % indicating that for every $100 in assets, the business produced a $28.23 loss. This is deeply below the industry norm. Similarly, it shows a return on stockholder's equity (ROE) of -100.18 %, suggesting that retained earnings are insufficient to offset equity losses.As of now, The current year's Common Stock Shares Outstanding is projected to rise to approximately 6.7 M, whereas Net Loss is moving lower toward about -23.2 M.
Stock Institutional Investors
Institutions hold about 7.48% of Evaxion Biotech AS while insiders own roughly 17.46%. Current market capitalization is about 31.94 Million. At that level, retail participation has a bigger role in day-to-day price moves. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. With moderate institutional presence, retail activity has more room to move the price day to day.
| Shares | Ubs Group Ag | 2025-09-30 | 1.0 | Beacon Capital Management, Llc | 2025-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2025-09-30 | 0.0 | Ikarian Capital, Llc | 2025-09-30 | 80 K | Rhumbline Advisers | 2025-12-31 | 21.1 K | Stonepine Capital Management Llc | 2025-12-31 | 20 K | Boothbay Fund Management, Llc | 2025-12-31 | 18.4 K | Smartharvest Portfolios, Llc | 2025-12-31 | 15.2 K | Wesbanco Bank Inc | 2025-12-31 | 10 K | Northwestern Mutual Wealth Management Co | 2025-12-31 | 8 K | Gamma Investing Llc | 2025-12-31 | 3.8 K |
Outstanding Bonds
Reviewing Evaxion Biotech AS bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| US29977LAA98 Corp BondUS29977LAA98 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 1.1 M | Current Value 6.4 M | Average Shares Outstanding 5.4 M | Quarterly Volatility 14.6 M |
Macro event markers
Holders Distribution
Institutional ownership analysis for Evaxion Biotech AS matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. The better interpretation comes from watching concentration, turnover, and changes in holder behavior instead of assuming institutional ownership is automatically bullish.
Market Cap and Value
Workforce Comparison
Evaxion Biotech AS is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is currently estimated at about 695. Evaxion Biotech holds roughly 46.0 in number of employees claiming about 7% of equities under Health Care sector.
Profit Margins
The company has Profit Margin (PM) of -1.02 %, which suggests a misalignment between pricing and cost structure. This is deeply below the industry norm. Similarly, it shows Operating Margin (OM) of -1.23 %, which indicates that operating costs are $1.23 in excess of revenue per $100 of sales.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.8 | 0.9 |
|
|
Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Evaxion Biotech AS Price Series Summation is a cross summation of Evaxion Biotech price series and its benchmark/peer.
Notable Stakeholders
Stakeholders matter for Evaxion Biotech because not every influential participant is a shareholder acting with the same objective or time horizon. The stronger interpretation comes from connecting stakeholder presence with management behavior, governance patterns, and changes in the operating story.
| Andreas MSc | Founder Officer | Profile | |
| Jesper MSc | Interim COO | Profile | |
| DMSC MD | Chief Officer | Profile | |
| Jrgen EMBA | Head Board | Profile | |
| Bo Karmark | Chief Officer | Profile | |
| Jesper Nissen | Chief Officer | Profile | |
| Thomas Schmidt | Interim Officer | Profile | |
| Helen TaytonMartin | Chief Officer | Profile | |
| Helen MBA | Chief Officer | Profile | |
| Per Norlen | Chief Officer | Profile | |
| Niels MD | VP CoFounder | Profile | |
| Benjamin Wolthers | Vice Development | Profile | |
| Andreas Mattsson | CoFounder Officer | Profile | |
| Christian MSc | Chief Officer | Profile | |
| Thomas MSc | Interim Officer | Profile | |
| Birgitte Rono | Interim Officer | Profile |
Management Information & Data Sources
Evaxion Biotech is a micro-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Insider activity can provide context on alignment between management and outside holders. Evaxion Biotech employs 46 people.
Unless otherwise specified, data for Evaxion Biotech AS is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst inputs may be included when coverage is available. Updates may occur throughout the day. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce metrics tied to Evaxion Biotech AS offer a useful way to test whether headcount and economic output are moving in a productive direction. The stronger interpretation compares these measures with sector norms because labor intensity varies meaningfully across industries.
Evaxion Biotech Manpower Efficiency
Return on Evaxion Biotech Manpower
| Revenue Per Employee | 164.2K | |
| Revenue Per Executive | 471.9K | |
| Net Loss Per Employee | 168.1K | |
| Net Loss Per Executive | 483.2K | |
| Working Capital Per Employee | 448.8K | |
| Working Capital Per Executive | 1.3M |
Popular Tools for Evaxion Stock analysis
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |